Today, we welcome ImmuCell Corporation, which trades on the NASDAQ under the ticker, ICCC. We’ll be engaging today with Michael Brigham, CEO of ImmuCell and a number of his sales team members in a discussion to give you a sense of the traction and the momentum they’re generating under flagship First Defense product and their revolutionary Re-Tain product, which is in the final stages of the FDA approval process and it’s been developed, they invested $2 billion annual loss experience by U.S. dairy producers due to mastitis.

This Fireside Chat was recorded during the Lytham Partners Summer 2022 Investor Conference.